Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pituitary Neoplasms 7Neuroendocrine Tumors 6Carcinoid Tumor 5Acromegaly 5Prostatic Neoplasms 4Pancreatic Neoplasms 4Gastro-enteropancreatic neuroendocrine tumor 3Pituitary ACTH Hypersecretion 2Neoplasms 2Neoplasm Metastasis 2Nelson Syndrome 2Multiple Myeloma 2Liver Neoplasms 2Growth Disorders 2Gigantism 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2ACTH Syndrome, Ectopic 2Uveal Melanoma 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Sarcoma, Synovial 1Prolactinoma 1Prolactin-Producing Pituitary Tumor 1Primary Inoperable Thymoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Fistula 1Neuroectodermal Tumors, Primitive 1

Interventions

fluorodopa F 18 4pasireotide 1gallium Ga 68 dotatate 1Insulin, Regular, Human 1Insulin 1Flour 1Diazoxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypoglycemia × pasireotide × Clear all
NCT02779257 2022-03-04

Pasireotide Treatment for Neuroendocrine Tumor

University of Maryland, Baltimore

Phase 4 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Hypoglycemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡